Anti-BRCA2抗体(ab27976)
Key features and details
- Rabbit polyclonal to BRCA2
- Suitable for: WB
- Reacts with: Human
- Isotype: IgG
选择批间可重复性更高的重组抗体
- 研究可靠 —— 各批次间结果一致且可重复
- 长期批量供应 —— 采用重组技术,可实现快速生产
- 首次实验即可成功 —— 经过大量验证确认了特异性
- 符合伦理标准 —— 产品不含动物成分
概述
-
产品名称
Anti-BRCA2抗体
参阅全部 BRCA2 一抗 -
描述
兔多克隆抗体to BRCA2 -
宿主
Rabbit -
经测试应用
适用于: WBmore details -
种属反应性
与反应: Human -
免疫原
Synthetic peptide mapping to the N terminus of human BRCA2.
-
常规说明
This product is manufactured by BioVision, an Abcam company and was previously called 3675 Anti-BRCA2 Antibody. 3675-100 is the same size as the 100 µg size of ab27976.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
性能
-
形式
Liquid -
存放说明
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles. -
存储溶液
Preservative: 0.03% Proclin 300
Constituents: PBS, 30% Glycerol (glycerin, glycerine), 0.5% BSA, 0.015% EDTA -
Concentration information loading...
-
纯度
Immunogen affinity purified -
纯化说明
This antibody is peptide affinity purified -
克隆
多克隆 -
同种型
IgG -
研究领域
相关产品
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
应用
The Abpromise guarantee
Abpromise™承诺保证使用ab27976于以下的经测试应用
“应用说明”部分 下显示的仅为推荐的起始稀释度;实际最佳的稀释度/浓度应由使用者检定。
应用 | Ab评论 | 说明 |
---|---|---|
WB | (3) |
Use a concentration of 1 - 4 µg/ml. Predicted molecular weight: 384 kDa.
|
说明 |
---|
WB
Use a concentration of 1 - 4 µg/ml. Predicted molecular weight: 384 kDa. |
靶标
-
功能
Involved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures. -
组织特异性
Highest levels of expression in breast and thymus, with slightly lower levels in lung, ovary and spleen. -
疾病相关
Defects in BRCA2 are a cause of susceptibility to breast cancer (BC) [MIM:114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.
Defects in BRCA2 are the cause of pancreatic cancer type 2 (PNCA2) [MIM:613347]. It is a malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.
Defects in BRCA2 are a cause of susceptibility to breast-ovarian cancer familial type 2 (BROVCA2) [MIM:612555]. A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate.
Defects in BRCA2 are the cause of Fanconi anemia complementation group D type 1 (FANCD1) [MIM:605724]. It is a disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair.
Defects in BRCA2 are a cause of glioma type 3 (GLM3) [MIM:613029]. Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. -
序列相似性
Contains 8 BRCA2 repeats. -
翻译后修饰
Phosphorylated by ATM upon irradiation-induced DNA damage.
Ubiquitinated in the absence of DNA damage; this does not lead to proteasomal degradation. In contrast, ubiquitination in response to DNA damage leads to proteasomal degradation. - Information by UniProt
-
数据库链接
- Entrez Gene: 675 Human
- Omim: 600185 Human
- SwissProt: P51587 Human
- Unigene: 34012 Human
-
别名
- BRCA 2 antibody
- BRCA1/BRCA2 containing complex subunit 2 antibody
- Brca2 antibody
see all
图片
数据表及文件
-
SDS download
-
Datasheet download
文献 (30)
ab27976 被引用在 30 文献中.
- Wang YC et al. Arginine shortage induces replication stress and confers genotoxic resistance by inhibiting histone H4 translation and promoting PCNA ubiquitination. Cell Rep 42:112296 (2023). PubMed: 36961817
- Jimenez-Sainz J et al. The Pathogenic R3052W BRCA2 Variant Disrupts Homology-Directed Repair by Failing to Localize to the Nucleus. Front Genet 13:884210 (2022). PubMed: 35711920
- Yoshinaga M et al. The N6-methyladenosine methyltransferase METTL16 enables erythropoiesis through safeguarding genome integrity. Nat Commun 13:6435 (2022). PubMed: 36307435
- Paul MW et al. Role of BRCA2 DNA-binding and C-terminal domain in its mobility and conformation in DNA repair. Elife 10:N/A (2021). PubMed: 34254584
- Saha A et al. Combinatorial Approaches to Enhance DNA Damage following Enzyme-Mediated Depletion of L-Cys for Treatment of Pancreatic Cancer. Mol Ther 29:775-787 (2021). PubMed: 33091613